granulocyte-macrophage colony-stimulating factor plasmid

Granulocyte-macrophage colony-stimulating factor plasmid is a plasmid DNA construct encoding the cytokine human granulocyte-macrophage colony-stimulating factor (GM-CSF). It acts as a molecular adjuvant, primarily by enhancing immune responses through induction of dendritic cell proliferation, maturation, and migration, as well as promoting B and T lymphocyte expansion and differentiation. The therapeutic strategy involves using the plasmid as a gene therapy or vaccine adjuvant to increase the immunogenicity of co-administered cancer antigens. GM-CSF DNA has shown potential in early-phase trials as an adjuvant in peptide and DNA vaccines for cancer, notably in melanoma, and has demonstrated a favorable safety profile with primarily mild injection site reactions. It does not function as a standalone cancer therapy but rather augments immune responses to specific antigens when given in combination therapies. The plasmid has been developed and tested clinically at institutions such as Memorial Sloan Kettering Cancer Center, with clinical grade supply produced by specialized manufacturers[1].

Other names

GM-CSF DNAhuman GM-CSF plasmid DNAgranulocyte-macrophage colony-stimulating factor DNA